Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Regulatory T cells are paramount effectors in progesterone regulation of embryo implantation and fetal growth
Ella S. Green, … , Shaun R. McColl, Sarah A. Robertson
Ella S. Green, … , Shaun R. McColl, Sarah A. Robertson
Published May 16, 2023
Citation Information: JCI Insight. 2023;8(11):e162995. https://doi.org/10.1172/jci.insight.162995.
View: Text | PDF
Research Article Reproductive biology

Regulatory T cells are paramount effectors in progesterone regulation of embryo implantation and fetal growth

  • Text
  • PDF
Abstract

Progesterone (P4) is essential for embryo implantation, but the extent to which the pro-gestational effects of P4 depend on the maternal immune compartment is unknown. Here, we investigate whether regulatory T cells (Treg cells) act to mediate luteal phase P4 effects on uterine receptivity in mice. P4 antagonist RU486 administered to mice on days 1.5 and 3.5 postcoitum to model luteal phase P4 deficiency caused fewer CD4+Foxp3+ Treg cells and impaired Treg functional competence, along with dysfunctional uterine vascular remodeling and perturbed placental development in midgestation. These effects were linked with fetal loss and fetal growth restriction, accompanied by a Th1/CD8-skewed T cell profile. Adoptive transfer at implantation of Treg cells — but not conventional T cells — alleviated fetal loss and fetal growth restriction by mitigating adverse effects of reduced P4 signaling on uterine blood vessel remodeling and placental structure and by restoring maternal T cell imbalance. These findings demonstrate an essential role for Treg cells in mediating P4 effects at implantation and indicate that Treg cells are a sensitive and critical effector mechanism through which P4 drives uterine receptivity to support robust placental development and fetal growth.

Authors

Ella S. Green, Lachlan M. Moldenhauer, Holly M. Groome, David J. Sharkey, Peck Y. Chin, Alison S. Care, Rebecca L. Robker, Shaun R. McColl, Sarah A. Robertson

×

Figure 7

Treg cells mitigate defective decidual vessel remodeling caused by impaired luteal phase P4 signaling.

Options: View larger image (or click on image) Download as PowerPoint
Treg cells mitigate defective decidual vessel remodeling caused by impai...
Female B6 mice were mated to BALB/c males and administered RU486 (1 mg/kg) or vehicle (control) on 1.5 and 3.5 dpc. On 3.5 dpc, approximately 8 hours following the final RU486 dose, females were injected i.v. with 2 × 105 Treg cells (CD4+CD25+), Tconv cells (CD4+CD25–), or vehicle control (PBS), and then decidual blood vessels were analyzed by histology in implantation sites collected on 9.5 dpc. (A) Representative images of cross sections of decidua stained with Masson’s trichrome to enable evaluation of decidual blood vessels. Scale bar = 100 μm (main images); scale bar = 50 μm (insets). (B) Total decidual vessel area, diameter, lumen area, and total/lumen area ratio were compared between groups. n = 6–7 pregnant dams/group were analyzed, with 1 implantation site per dam randomly selected for analysis. Data are shown as mean ± SEM with individual mice indicated by symbols. Data were analyzed by 1-way ANOVA with Sidak’s post hoc t test, *P < 0.05.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts